MedTrace Logo

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

NCT04552223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.

Conditions

  • Metastatic Uveal Melanoma

Interventions

DRUG

Nivolumab

Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.

DRUG

Relatlimab

Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • United States Department of Defense

    collaborator FED

  • Jose Lutzky, MD

    lead OTHER

Principal Investigators

  • Jose Lutzky, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-10
Primary Completion
2024-01-04
Completion
2026-01-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552223 on ClinicalTrials.gov